Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection - PubMed (original) (raw)
Case Reports
Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection
Susanna Esposito et al. J Clin Virol. 2010 May.
Abstract
Background: Oseltamivir is considered the drug of choice for patients with pandemic influenza for whom drug treatment is recommended because adamantanes seem to be ineffective against pandemic A/H1N1 influenza virus and zanamivir is contraindicated in people with underlying respiratory conditions and difficult to administer in younger children.
Objectives: To increase knowledge on oseltamivir resistance emergence in pandemic A/H1N1 influenza.
Study design: Description of the case of an 8-year-old boy with cystic fibrosis and Pseudomonas aeruginosa infection in whom an oseltamivir-resistant pandemic A/H1N1 influenza virus was demonstrated.
Results: On the basis of clinical and virological failure (nasopharyngeal secretions remained positive for pandemic A/H1N1 influenza virus and appearance of 275Y mutation in 100% virus population) on fifth day of treatment, oseltamivir was replaced by zanamivir inhalation (5mg to be inhaled twice a day). This change was associated with a rapid improvement in the patient's general condition, respiratory findings and laboratory data (including disappearance of pandemic A/H1N1 influenza virus) in the absence of any adverse event.
Conclusions: The emergence of oseltamivir-resistant strains is related to the administration of the drug, supporting the restriction of oseltamivir use to carefully defined high-risk groups. Infection due to pandemic virus with the H275Y mutation can be associated with a severe clinical course, supporting the systematic monitoring of antiviral susceptibility in pandemic influenza-positive high-risk patients whose influenza is not resolved by oseltamivir treatment. Zanamivir inhalation can be successfully used in patients with cystic fibrosis without causing adverse respiratory events, highlighting that the risks and benefits of this drug must be considered on a patient by patient basis.
Copyright 2010 Elsevier B.V. All rights reserved.
Similar articles
- Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections.
Wang B, Dwyer DE, Blyth CC, Soedjono M, Shi H, Kesson A, Ratnamohan M, McPhie K, Cunningham AL, Saksena NK. Wang B, et al. Antiviral Res. 2010 Jul;87(1):16-21. doi: 10.1016/j.antiviral.2010.04.002. Epub 2010 Apr 10. Antiviral Res. 2010. PMID: 20385168 - Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, Yamauchi S, Kawamura K, Matsuura S, Nishimura M, Iwaki N, Kashiwagi S. Kawai N, et al. Clin Infect Dis. 2009 Dec 15;49(12):1828-35. doi: 10.1086/648424. Clin Infect Dis. 2009. PMID: 19911968 - Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.
Centers for Disease Control and Prevention (CDC). Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2009 Sep 11;58(35):969-72. MMWR Morb Mortal Wkly Rep. 2009. PMID: 19745803 - The use of antiviral agents for the management of severe influenza.
Smith JR, Ariano RE, Toovey S. Smith JR, et al. Crit Care Med. 2010 Apr;38(4 Suppl):e43-51. doi: 10.1097/CCM.0b013e3181c85229. Crit Care Med. 2010. PMID: 19935416 Review. - Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Ikematsu H, Kawai N. Ikematsu H, et al. Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. doi: 10.1586/eri.11.112. Expert Rev Anti Infect Ther. 2011. PMID: 21973296 Review.
Cited by
- H1N1 Influenza Virus in Patients With Cystic Fibrosis: A Literature Review Examining Both Disease Entities and Their Association in Light of the 2009 Pandemic.
Wiltshire DA, Vahora IS, Tsouklidis N, Kumar R, Khan S. Wiltshire DA, et al. Cureus. 2020 Jul 16;12(7):e9218. doi: 10.7759/cureus.9218. Cureus. 2020. PMID: 32821569 Free PMC article. Review. - Drugs for Influenza Treatment: Is There Significant News?
Principi N, Camilloni B, Alunno A, Polinori I, Argentiero A, Esposito S. Principi N, et al. Front Med (Lausanne). 2019 May 28;6:109. doi: 10.3389/fmed.2019.00109. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31192211 Free PMC article. Review. - Molecular distribution of amino acid substitutions on neuraminidase from the 2009 (H1N1) human influenza pandemic virus.
Quiliano M, Valdivia-Olarte H, Olivares C, Requena D, Gutiérrez AH, Reyes-Loyola P, Tolentino-Lopez LE, Sheen P, Briz V, Muñoz-Fernández MA, Correa-Basurto J, Zimic M. Quiliano M, et al. Bioinformation. 2013 Jul 17;9(13):673-9. doi: 10.6026/97320630009673. Print 2013. Bioinformation. 2013. PMID: 23930018 Free PMC article. - Next-generation direct-acting influenza therapeutics.
Toots M, Plemper RK. Toots M, et al. Transl Res. 2020 Jun;220:33-42. doi: 10.1016/j.trsl.2020.01.005. Epub 2020 Feb 4. Transl Res. 2020. PMID: 32088166 Free PMC article. Review. - Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM).
Pedrazzoli P, Baldanti F, Donatelli I, Castrucci MR, Puglisi F, Silvestris N, Cinieri S; Italian Society of Medical Oncology. Pedrazzoli P, et al. Ann Oncol. 2014 Jun;25(6):1243-7. doi: 10.1093/annonc/mdu114. Epub 2014 Mar 11. Ann Oncol. 2014. PMID: 24618150 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical